Korro Bio is a biotechnology company focused on developing RNA editing technologies to create new treatments for patients with debilitating and life-threatening diseases. The company's foundational platform for RNA editing, Oligonucleotide Promoted Editing of RNA (OPERA), is inspired by natural processes to make reversible changes to genetic instructions.

Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Atlas Venture

New Enterprise Associates

Alexandria Venture Investments

Wu Capital

MP Healthcare Venture Management

Surveyor Capital

Cormorant Asset Management

Qiming Venture Partners USA

Monashee Investment Management

Invus

Verition Fund Management

Fidelity

Point72

Sixty Degree Capital

Fidelity Management and Research Company

We’re pleased to announce that Korro Bio will be attending the TD Cowen 44th Annual Health Care Conference in Boston.

Our Chief Executive Officer and President, Ram Aiyar, Ph.D., will present on Monday, March 4, 2024, at 2:10 PM ET.

Tune in for a live webcast of the presentation at: https://ir.korrobio.com/

https://lnkd.in/eT4CnDQr

#KorroBio #TDCowen #TDCowenHealthCare Cowen Inc.

#ICYMI, the Korro team attended the Nasdaq Closing Bell Ringing Ceremony on Tuesday. Thank you to Nasdaq for hosting us and your collaboration. Our team had an incredibly humbling moment celebrating our success.

Here's to Korro’s ongoing innovation as we advance #RNAediting.

Missed the livestream? Catch the recording here: https://lnkd.in/eZkjHPRS 

#KorroBio #ClosingBell

We are pleased to announce the key highlights from our presentation at the J.P. Morgan Healthcare Conference last week. We shared data for our lead program in Alpha-1 Antitrypsin Deficiency (AATD) and our pipeline.  

To read more about our recent accomplishments, see the full press release: bit.ly/3HncrAX

To view our corporate presentation, go to: https://bit.ly/3vEWOCx 

#JPM2024 #JPMorganHealthcare #KorroBio

We invite you to tune in to the live webcast today at 11:15 am PT / 2:15 pm ET. Our CEO and President, Ram Aiyar, will share the corporate update at the J.P. Morgan Healthcare Conference. Learn more about our progress in expanding the frontiers of genetic medicines through #RNAediting.

To view the presentation, visit: bit.ly/41VtvHN

To listen to the webcast, go to: https://lnkd.in/g4n4jJqk

Vineet Agarwal Steve Colletti

#JPMorganHealthcare #JPM2024 #KorroBio

KRRO

COM:KORROBIO

Korro Bio

Last Close

50.62

22/11 21:00

Market Cap

385.94M

Beta: -

Volume Today

67.40K

Avg: -

name

homepage url

country

linkedin url

crunchbase url

employee count

sector

industry

Description

investor of

Metrics